WSW, NY, March 11th, 2026, FinanceWire
While the market piles into missile manufacturers and drone companies, MediWound (NASDAQ: MDWD) is quietly positioned inside the government’s mass-casualty preparedness infrastructure, with a Phase III catalyst ahead
Defense stocks are having their moment. Palantir (NYSE: PLTR) has surged past $150 on the back of government AI contracts and 70% revenue growth. Elbit Systems (NASDAQ: ESLT) just crossed $880 with record backlogs. Kratos Defense (NASDAQ: KTOS) has nearly tripled. The catalyst is obvious: NATO allies are rearming at a pace not seen since the Cold War, and years of rising tensions between the U.S., Israel, and Iran have now spilled into what is looking increasingly like a regional war.
But the defense trade has a blind spot. Nearly all of the capital has flowed into kinetic systems: drones, missiles, radar, cyber. Almost none has gone to what governments need after the explosions stop. Medical countermeasures for mass-casualty events remain deeply underfunded by the market. That is where MediWound (NASDAQ: MDWD) sits, and the setup is increasingly hard to ignore.
Already Inside the System
MediWound’s lead product, NexoBrid, is the only FDA-approved enzymatic debridement agent for severe burns. In plain terms, it replaces surgery. The standard of care requires an operating room, anesthesia, and a specialist surgical team. NexoBrid does it with a four-hour topical application. No scalpel. No OR. In a mass-casualty scenario, that distinction is the difference between a treatment that scales and one that does not.
The U.S. government has already placed its bet. BARDA, the Biomedical Advanced Research and Development Authority, has awarded $120 million in non-dilutive funding to MediWound for NexoBrid’s development, manufacturing, and procurement under a Project BioShield contract. NexoBrid received FDA approval in December 2022 and is now in the U.S. Strategic National Stockpile. That $120 million is more than half the size of MediWound’s entire current market capitalization, a seemingly striking imbalance for a company with a validated government franchise.
The Spending Environment Has Never Been Better
European NATO members have added over $160 billion in annual defense spending since 2022. The NATO Hague Summit set a new target of 3.5% of GDP by 2035, roughly double current European levels. In December 2023, the European Commission allocated €690 million to build rescEU strategic reserves of medical and CBRN response items. NATO’s updated framework now allows member states to count civil preparedness spending toward their defense commitments, expanding the addressable budget for products like NexoBrid.
This week’s events make the case in real time. The U.S. and Israel are engaged in active strikes on Iran, with retaliatory responses across the region sending defense names sharply higher. But the procurement cycle does not end with missiles. Governments at war are also restocking the medical supply chain, and NexoBrid is the only approved product in its category with a decade of government validation behind it.
The Bigger Catalyst: EscharEx
The government burn franchise is what makes MDWD worth watching now. But the larger opportunity is EscharEx, a second-generation enzymatic debridement agent in Phase III development for chronic wounds. The target is a $360-million-a-year U.S. market currently dominated by Smith & Nephew’s SANTYL, a 60-year-old product with no robust Phase III data and no meaningful competition.
MediWound’s Phase II study showed EscharEx achieved faster complete debridement and a median time to wound closure of 48 days versus 76 days for SANTYL. Across three Phase II studies, EscharEx consistently achieved complete debridement in an average of 4-5 days. Published data for SANTYL suggests it hits the same endpoint in 4-8 or more weeks. The mechanism is fundamentally different: where SANTYL cleaves only collagen at seven sites, EscharEx deploys a multimodal proteolytic suite of enzymes that simultaneously removes necrotic tissue, reduces biofilm, and prepares the wound bed. MediWound is currently conducting VALUE, a global Phase III pivotal trial in venous leg ulcers. A pre-specified interim analysis and competition of patient enrollment is expected by year-end 2026.
If the Phase III data confirms Phase II, EscharEx would be entering a commercial market more than 10x the size of the acute burn category, against an incumbent that has coasted without competition for decades.
The Bottom Line
For those looking for defense exposure beyond the obvious names, the medical preparedness layer is looking increasingly interesting and under-the-radar. MediWound is a small-cap biotech trading with a government-validated product already in the Strategic National Stockpile, that could benefit from a spending tailwind that is accelerating on both sides of the Atlantic, and a Phase III readout that could reframe the entire company.
This content is an excerpt of a new report published by Calypso Research. The full report is available using the following link: https://calypsoresearch.com/MDWD/090326
Recent News Highlights from MediWound
MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from MediWound Ltd for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article should not be considered an official communication of the issuer.